Valentin Gutierrez-Garcia
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 133 publications
Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 30, 2026
Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 02, 2026
Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.
Journal: British journal of haematology
Published: May 14, 2026
Ponatinib Safety Profile: An Analysis of 10 Years of Real-World Experience.
Journal: Drug safety
Published: March 31, 2026
Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera.
Journal: Blood cancer journal
Published: January 30, 2026
Impact of Atrial Fibrillation on the Risk of Thrombosis and Bleeding for Patients With Polycythemia Vera and Essential Thrombocytosis in the Real World.
Journal: American journal of hematology
Published: January 19, 2026
Correction: Immune response dynamics of SARS-CoV-2 vaccination in chronic lymphocytic leukemia individuals: a descriptive analysis.
Journal: Frontiers in immunology
Published: September 16, 2025
Platelet Proteome Links Metabolism to Reactivity in Essential Thrombocythemia.
Journal: Molecular & cellular proteomics : MCP
Published: April 16, 2025
Immune response dynamics of SARS-CoV-2 vaccination in chronic lymphocytic leukemia individuals: a descriptive analysis.
Journal: Frontiers in immunology
Published: February 05, 2025
Last Updated: 09/26/2026